This flu season is ramping up earlier than last year's, NBC News reports.» Read More
The arrival of two U.S. Ebola patients and the testing of ill patients that recently traveled from West Africa have created fears. But are they genuine?
A lawsuit by Allergan says the unusual arrangement by Valeant Pharmaceuticals and activist investor Bill Ackman amounts to insider trading.
Sapphire glass and biotech companies are bringing out the bears ahead of this week's earnings.
The death toll from the Ebola virus in West Africa keeps growing to record levels. And ironically, that may be why there's no vaccine, said an expert.
Regulators are considering new rules to make pot-infused treats look different even when they're out of the packages.
West African leaders and international health groups have stepped up plans to combat the world’s worst outbreak of the deadly Ebola virus.
The US Peace Corps said it was withdrawing 340 volunteers from Liberia, Sierra Leone and Guinea due to the spreading Ebola virus across West Africa.
CNBC's Jim Cramer on Wednesday identified two biotechnology stocks that he thinks could climb.
AstraZeneca took steps to build up its respiratory medicine business by striking a deal to acquire the rights to lung drugs developed by Almirall.
Regeneron Pharmaceuticals said the U.S. Food and Drug Administration has approved the use of Eylea for the treatment of diabetic macular edema.
Amgen posted higher-than-expected profit and said it would cut 12 to 15 percent of its workforce and close two plants.
Pfizer CEO Ian Read also says a potential U.S. tax holiday would be only a temporary solution.
Pfizer reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.
Merck reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
Reckitt Benckiser plans to spin off its heroin-addiction treatment in the next 12 months as sales slide under pressure from rival versions.
GSK's chief executive has opened the possibility of the group being broken up as he pushes through a sweeping overhaul of Britain's biggest drugmaker.
Gilead Sciences delivered quarterly earnings and revenue that topped analysts' expectations on Wednesday.
CNBC's Dominic Chu takes a look at the big movers in biotech on Wednesday.
U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.
Get the best of CNBC in your inbox